Emergent BioSolutions, Rocketvax announce investment agreement

Emergent BioSolutions (EBS) and Rocketvax announced entry into an agreement for Emergent’s strategic financial investment into Swiss Rockets, the parent company of Rocketvax to support research, infrastructure development, and the expansion of Swiss Rockets’ biotechnology portfolio. In addition to the investment, the parties intend to form a strategic partnership whereby Emergent would lead the U.S. manufacturing and commercialization efforts for four of Rocketvax’s pipeline candidates for infectious diseases, cancer, and autoimmune disorders. For one of these pipeline candidates, Rocketvax Ltd has already signed a letter of intent with the U.S. National Institutes of Health. The Rocketvax / NIH collaboration is part of the Project NextGen initiative and will support a clinical trial investigating a next generation vaccine using Rocketvax proprietary technology. One of Rocketvax’s leading candidates is a live-attenuated nasal spray SARS-CoV-2 vaccine, which has demonstrated superior efficacy compared to mRNA COVID-19 vaccines in animal studies. Live-attenuated vaccines mimic natural infections more closely, often providing stronger and longer-lasting immunity by stimulating a broader immune response, including mucosal immunity, which is crucial for respiratory infections.